Director Anne O'Riordan not standing for re-election at Jazz's 2026 annual meeting

Jazz Pharmaceuticals plc

Class III director Anne O'Riordan will not seek re-election at the 2026 annual meeting, continuing board refreshment.
O'Riordan's decision was not due to any dispute or disagreement with the company or board.
Board will continue to evaluate composition; no immediate replacement announced.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Anne O'Riordan

Director

JAZZ · Jazz Pharmaceuticals plc

Effective: 2026-05-25
Filed: May 29, 2026, 4:05 PM ET

On May 25, 2026, Anne O’Riordan, a Class III director whose term expires at the Jazz Pharmaceuticals plc (the “Company”) 2026 annual meeting of shareholders, has informed the board of directors (the “Board”) that she will not stand for re-election.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Anne O'Riordan departed as Director at Jazz Pharmaceuticals plc.

Action: not stand for re-election
Role: Director

Exact text from the filing

On May 25, 2026, Anne O’Riordan, a Class III director whose term expires at the Jazz Pharmaceuticals plc (the “Company”) 2026 annual meeting of shareholders, has informed the board of directors (the “Board”) that she will not stand for re-election.

View on SEC.gov

Jazz Pharmaceuticals plc filing history →

Source: SEC EDGAR

accession 0001628280-26-039147

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.